Want to see AU:EMV full AI Analyst Report?

EMvision Medical Devices Ltd. (EMV) Price & Analysis

6 Followers

EMV Stock Chart & Stats

AU$1.77

-AU$0.06(-3.19%)

At close: Jan 09 4:00 PM EST

AU$1.77

-AU$0.06(-3.19%)

Day’s Range― - ―

52-Week RangeAU$1.47 - AU$2.43

Previous CloseN/A

Volume36.00K

Average Volume (3M)120.98K

Market Cap

AU$150.59M

Enterprise ValueAU$127.28M

Total Cash (Recent Filing)AU$17.56M

Total Debt (Recent Filing)AU$4.02M

Price to Earnings (P/E)―

Beta0.66

Next Earnings

Sep 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding92,955,560

10 Day Avg. Volume127,185

30 Day Avg. Volume120,982

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)16.01

Price to Sales (P/S)29.42

P/FCF Ratio-18.85

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$3.15

Price Target Upside77.97% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.11

Revenue Forecast (FY)AU$5.00M

Bulls Say, Bears Say

Bulls Say

Focused Product StrategyEMvision targets a defined clinical niche—portable electromagnetic brain imaging for emergency and pre-hospital use. This focus aligns with durable demand for faster stroke/TBI diagnostics and supports a differentiated product roadmap and go-to-market efforts that can sustain adoption over months as hospitals and EMS seek point-of-care solutions.

Moderate LeverageA debt-to-equity ratio of 0.38 suggests the company is not highly leveraged, which reduces near-term solvency risk. This financial conservatism preserves capacity to raise funds for R&D or commercialization, limits interest burden, and gives management room to execute a multi-quarter development and market-entry plan without immediate creditor pressure.

Very High Gross MarginA reported 100% gross margin implies minimal direct cost of goods relative to revenue or favorable revenue recognition for the product. If maintained with scale, such margins create strong operating leverage, enabling the company to cover fixed R&D and sales costs and move toward profitability as commercial traction improves over multiple quarters.

Bears Say

Steep Revenue DeclineA 37% year-over-year revenue contraction signals material commercialization or demand problems. Sustained top-line declines reduce ability to fund clinical validation, sales rollout, and regulatory steps internally, undermining the timeline to reach scale and making multi-quarter recovery and sustainable growth more challenging without external funding or strategic pivots.

Consistent Negative Cash FlowPersistent negative operating and free cash flows mean the business consumes cash to operate and is trending worse. Over several months this forces reliance on external capital, increases dilution risk, and constrains investment in commercialization, clinical studies, or regulatory filings that are required to convert the technology into recurring revenue streams.

Ongoing Losses & Weak ReturnsNegative ROE and sustained operating losses show the company has not yet translated R&D and assets into shareholder returns. Over a multi-month horizon this raises concerns about the viability of current business plans, potential for repeated capital raises, and the company’s ability to retain investor and stakeholder support during commercialization.

EMvision Medical Devices Ltd. News

EMVision Advances Pivotal Brain Scanner Trial and Strengthens Funding Base

EMvision Medical Devices Ltd. ( ($AU:EMV) ) has shared an announcement. EMVision reported strong progress in its pivotal...

7d ago

EMV

EMVision Secures Nature-Portfolio Validation for AI Stroke Scanner

EMvision Medical Devices Ltd. ( ($AU:EMV) ) just unveiled an update. EMVision’s EMView study, using its emu™ RF...

8d ago

EMV

EMVision aeromedical trial de-risks rural stroke scanner deployment

EMvision Medical Devices Ltd. ( ($AU:EMV) ) has shared an update. EMVision Medical Devices has completed a feasibility...

2M ago

EMV

EMVision issues new shares under employee incentive plan with cleansing notice

An announcement from EMvision Medical Devices Ltd. ( ($AU:EMV) ) is now available. EMVision Medical Devices has issued...

2M ago

EMV

EMvision Lists New Tranche of Ordinary Shares on ASX

EMvision Medical Devices Ltd. ( ($AU:EMV) ) has shared an announcement. EMvision Medical Devices Ltd., an ASX-listed medtech...

2M ago

EMV

EMVision expands pivotal emu brain scanner trial to include acute ischaemia detection

An announcement from EMvision Medical Devices Ltd. ( ($AU:EMV) ) is now available. EMVision is expanding the scope...

2M ago

EMV

EMvision Director Increases Stake with On-Market Share Purchase

EMvision Medical Devices Ltd. ( ($AU:EMV) ) has shared an announcement. EMvision Medical Devices has reported a change...

3M ago

EMV

EMVision Advances Pivotal Brain Scanner Trial as Cash Runway Strengthens

EMvision Medical Devices Ltd. ( ($AU:EMV) ) just unveiled an update. EMVision reported solid progress in its pivotal...

3M ago

EMV

EMvision Issues 60,000 Unquoted Performance Rights Under Employee Incentive Scheme

The latest update is out from EMvision Medical Devices Ltd. ( ($AU:EMV) ). EMvision Medical Devices Ltd. has...

3M ago

EMV

S&P Dow Jones Revises March 2026 All Ordinaries Rebalance

EMvision Medical Devices Ltd. ( ($AU:EMV) ) has provided an update. S&P Dow Jones Indices has updated its...

4M ago

EMV

EMV FAQ

What was EMvision Medical Devices Ltd.’s price range in the past 12 months?

EMvision Medical Devices Ltd. lowest share price was AU$1.47 and its highest was AU$2.43 in the past 12 months.

What is EMvision Medical Devices Ltd.’s market cap?

EMvision Medical Devices Ltd.’s market cap is AU$150.59M.

When is EMvision Medical Devices Ltd.’s upcoming earnings report date?

EMvision Medical Devices Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 43 days.

How were EMvision Medical Devices Ltd.’s earnings last quarter?

EMvision Medical Devices Ltd. released its earnings results on Feb 22, 2026. The company reported -AU$0.044 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.044.

Is EMvision Medical Devices Ltd. overvalued?

According to Wall Street analysts EMvision Medical Devices Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does EMvision Medical Devices Ltd. pay dividends?

EMvision Medical Devices Ltd. does not currently pay dividends.

What is EMvision Medical Devices Ltd.’s EPS estimate?

EMvision Medical Devices Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does EMvision Medical Devices Ltd. have?

EMvision Medical Devices Ltd. has 92,955,560 shares outstanding.

What happened to EMvision Medical Devices Ltd.’s price movement after its last earnings report?

EMvision Medical Devices Ltd. reported an EPS of -AU$0.044 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of EMvision Medical Devices Ltd.?

Currently, no hedge funds are holding shares in AU:EMV

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

EMvision Medical Devices Ltd. Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

25.56%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

EMvision Medical Devices Ltd.

EMVision Medical Devices Limited is an Australian enterprise specializing in the innovation, development, and market introduction of advanced imaging and diagnostic healthcare technologies. The company's principal offering is a compact, mobile brain scanner engineered for the swift detection and continuous tracking of strokes, in addition to fulfilling other medical imaging necessities. Founded in 2017, its operations are headquartered in Macquarie Park.

EMvision Medical Devices Ltd. (EMV) Earnings & Revenues

Historic Earnings Reports

EMV Stock 12 Month Forecast

Average Price Target

AU$3.15

▲(77.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","2":"AU$2","3":"AU$3","4":"AU$4"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$3.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$3.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$3.15</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1,2,3,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.49,1.6176923076923078,1.7453846153846153,1.873076923076923,2.000769230769231,2.128461538461538,2.256153846153846,2.3838461538461537,2.5115384615384615,2.6392307692307693,2.766923076923077,2.894615384615385,3.0223076923076926,{"y":3.15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.49,1.6176923076923078,1.7453846153846153,1.873076923076923,2.000769230769231,2.128461538461538,2.256153846153846,2.3838461538461537,2.5115384615384615,2.6392307692307693,2.766923076923077,2.894615384615385,3.0223076923076926,{"y":3.15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.49,1.6176923076923078,1.7453846153846153,1.873076923076923,2.000769230769231,2.128461538461538,2.256153846153846,2.3838461538461537,2.5115384615384615,2.6392307692307693,2.766923076923077,2.894615384615385,3.0223076923076926,{"y":3.15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.74,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.89,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.775,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.755,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >